Advanced Filters
noise
Found 1,877 clinical trials
Z Zhe Ji, M.D.

I-125 Seeds Implantation in the Treatment of Recurrent Lung Cancer After Radiotherapy

Patients with recurrence after radiotherapy are often encountered in clinical practice.Patients with recurrence after radiotherapy are less likely to undergo surgery or secondary radiotherapy, and the guidelines recommend only systemic therapy, although the effective rate is relatively low.For patients with local recurrence without distant metastasis, local treatment is still significant.Radioactive …

18 - 75 years of age All Phase N/A

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main …

years of age All Phase N/A
N Nan Bi, MD, PhD

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

This study is a prospective cohort study to evaluate the peripheral blood lymphocyte subsets as predicative biomarkers reflecting the efficacy and toxicity in patients with locally advanced non-small cell lung cancer (NSCLC) received chemoradiotherapy (CRT) with or without immune checkpoint inhibitors (ICIs).

18 - 75 years of age All Phase N/A

Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer

This trial is a multicenter, open-label, non-interventional controlled study to identify and characterize epigenetic signatures of lung cancer. The goal of this study is to develop a simple blood test that can detect lung cancer with high sensitivity, and assist in the early diagnosis and management of lung cancer. In …

18 years of age All Phase N/A

Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

The primary objective of this study is to characterize the safety profile of sotorasib.

18 years of age All Phase N/A
S Sam Springer, MSc

Evaluation of the Use of the FUR to Quantify Tumor Glucose Consumption in Oncologic PET

The goal of this study is to evaluate the use of new method to quantify the amount of sugar a tumor consumes using PET/CT. The main questions it aims to answer are: Is the new quantification method superior with respect to the method currently used in the clinic? Does the …

18 years of age All Phase N/A

Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir

This is a open-label, multi-center prospective observation study for the efficacy and safety of intraventricle pemetrexed disodium via ommaya reservoir in the treatment of leptomeningeal metastasis with lung cancer who have failed at least one targeted therapy. In detail: At least the treatment failure was after third-generation EGFR-TKIs in EGFR-mutated …

18 years of age All Phase N/A

A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)

To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac.

18 years of age All Phase N/A
B Benjamin D Kozower, M.D., MPH

Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer

The development of stereotactic body radiation therapy (SBRT) for the treatment of stage I non-small cell lung cancer (NSCLC) has inspired a close partnership between thoracic surgery and radiation oncology. In this study, patients with stage I NSCLC will be screened prior to treatment and will be consented after their …

18 years of age All Phase N/A
X Xiaomin Niu

Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer

Immunotherapy has improved the prognosis of non-small cell lung cancer (NSCLC) patients, but about 80% of patients do not respond at all, which is called primary resistance. Absence of the PD-L1 expression is regarded as one of primary resistant reasons to immunotherapy, there are some other reasons which have been …

18 years of age All Phase N/A

Simplify language using AI